Hyperfine, Inc., a health technology company, engages in the production, supply, service, and commercialization of magnetic resonance imaging (MRI) products. Its Swoop ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
[url="]Hyperfine, Inc.[/url] (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered
GUILFORD, Conn.--(BUSINESS WIRE)--Peer-reviewed NEURO PMR results and 3,000+ office brain MRI scans support growing use of the Swoop system across neurology practices.
[url="]Hyperfine, Inc.[/url] (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered
GUILFORD, Conn.--(BUSINESS WIRE)--FDA-cleared Optive AI software enhances Swoop system image quality, clinical utility, ease of use, and isotropic imaging capability.
Hyperfine, Inc. (HYPR) Q2 2026 Earnings Call Transcript
[url="]Hyperfine, Inc.[/url] (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered
GUILFORD, Conn.--(BUSINESS WIRE)--Peer-reviewed NEURO PMR results and 3,000+ office brain MRI scans support growing use of the Swoop system across neurology practices.
[url="]Hyperfine, Inc.[/url] (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered
GUILFORD, Conn.--(BUSINESS WIRE)--FDA-cleared Optive AI software enhances Swoop system image quality, clinical utility, ease of use, and isotropic imaging capability.
Hyperfine, Inc. (HYPR) Q2 2026 Earnings Call Transcript
Hyperfine NASDAQ: HYPR reported second-quarter revenue of $3.9 million, up approximately 45% from a year earlier, as the portable MRI company cited growth across hospital, neurology office and international markets.
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance (MR) brain imaging system—the Swoop® system—today announced second quarter 2026 financial results and provided a business update. “Q2 was another strong quarter for Hyperfine, marked by solid growth in placements and revenue, continued gross margin expansion, disciplined operating expense.
GUILFORD, Conn.--(BUSINESS WIRE)--Multiple peer-reviewed publications in Journal of Neurosurgery and Stroke strengthen evidence for portable MRI in stroke and neurosurgical settings.
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine will report Q2 2026 financial results Thur., Aug. 6, 2026. Management will host a corresponding conference call at 1:30 PM PT/4:30 PM ET.
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine initiates the launch of the next-gen Swoop® system in Europe, beginning global expansion of its most advanced portable MRI technology. .
GUILFORD, Conn.--(BUSINESS WIRE)--Leading neurosurgeons will help guide the role of the Swoop® system in neurosurgical care, including workflow, product capabilities, and evidence.
[url="]Hyperfine, Inc.[/url] (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powere
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine announces Swoop® system scan volume milestones at key hospitals and neurology clinics, demonstrating accelerating adoption across the US.
Hyperfine, Inc. (HYPR) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
